Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2007

View Archived Issues

New compounds for respiratory disorders claimed in recent patent literature

Monarsen improves myasthenia gravis status

Cognitive function not worsened in children with behavior disorders given risperidone

YM-150 effective and safe as venous thromboembolism prophylaxis

Axcan Pharma announces third quarter 2007 results

New antiinfective compounds described in recent patent literature

Antigenics reports second quarter 2007 results

PTC Therapeutics patents disclose novel compounds for HCV infections

Positive results for Antisoma's ASA-404 in phase II lung cancer trial

Newron and Merck report preliminary results of safinamide phase III trial for PD

Alpharma and Institut Biochimique sign NSAID patch marketing agreement

FDA grants orphan drug designation to Pharmion and MethylGene's MGCD-0103

Abraxis BioScience and TRSI enter epothilone licensing agreement for cancer

Genta begins phase III trial of Genasense for advanced melanoma

Interim data from phase II trial of HIV vaccine tgAAC-09 reported by Targeted Genetics

Daiichi Sankyo and Forest to copromote antihypertensive drug Azor

Eisai receives approval for additional efficacy and dosage for Aricept in Japan

SARMs designed at BMS with selectivity for muscle over prostate

Promising 11beta.-HSD1 inhibitor with potential in endocrine and metabolic disorders

Potential migraine therapeutics in development at Merck

Fast track designation for Marqibo in treatment of relapsed ALL

AstraZeneca profiles series of dual CXCR2/CCR2B antagonists for inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.